HIMS — Hims & Hers Health, Inc. Class A Common Stock

HIMS — 오늘 왜 언급됐나 (2026-10-29)

• HHS가 규제 검토 기간 중 BPC-157 등 인기 펩타이드의 조제약 생산을 임시로 허용한다고 발표하자 주가가 5.2% 상승했다.
• 11월 2일 대표 원고 선정 마감일을 앞두고, 손실을 입은 투자자들을 위한 증권 집단 소송이 제기되었다고 보도되었다.

Why people talked about HIMS

• HIMS shares rose 5.2% after the HHS allowed compounding pharmacies to produce popular peptides like BPC-157 during regulatory review.
• A securities class action was announced with a lead plaintiff deadline of November 2, 2026, encouraging investors with losses to contact Hagens Berman.
• The stock was listed among those likely to 10X over the next decade, with a recent price noted at $29.032.